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Cancer-induced immunosuppression is one of the major
problems for development of cancer immunotherapies.
A transcriptional factor HNF-1b preferentially activated
in human ovarian clear cell cancer (OCCC) was reported
to contribute to various malignant features including
metastases and glucose metabolism. In this study, we
have investigated roles of HNF-1b in the immunosup-
pressive activity of human OCCC. HNF-1b knockdown
and overexpression experiments revealed that HNF-1b
induced production of IL6 and IL8, which were elevated
in OCCC patient plasma. HNF-1b was found to promote
production of IL6 and IL8 through activated STAT3
signaling and NF-B dependent osteopontin pathway. In
vitro suppressive activities of human OCCC culture
supernatants on generation of human monocyte-derived
dendritic cell (DC) were reduced by siRNA knockdown
of HNF-1b in cancer cells partly through decrease of IL6
production. In the nude mice implanted with human
OCCC cell lines, knockdown of HNF-1b in the cancer
cells resulted in restoration of T cell stimulatory activity
of murine splenic DC, and decrease of accumulation and
arginase expression of myeloid-derived suppressor cells
in spleens and tumors accompanied by human IL6
decrease. In the OCCC patient plasma, IL8 levels were
correlated with the levels of immunosuppressive arginase,
indicating that IL8 may also be involved in immunosup-
pression. Therefore, HNF-1b activation in human OCCC
is an upstream event for induction of immunosuppres-
sion via STAT3 and NF-B activation, and is an attrac-
tive target for restoring immunocompetence in OCCC
patients.
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